PMV Pharmaceuticals, Inc. PMVP
1.38 USD +0.01 (+0.73%)
At closeNov 3, 2026, 4:02 PM EST
1.38 0.00 0.00%
After hours · Nov 3, 4:02 PM ET
1.33 Day range 1.42
1.02 52-week range 1.91
- YTD
- +10.40%
- 1 year
- -1.43%
- Market cap
- 104.21M
- EPS (ttm)
- -1.42
- Shares out
- 51.75M
- Forward P/E
- -0.96
- YTD return
- +10.40%
- 1-year return
- -1.43%
- Volume
- 458.25K
- Avg volume
- 660.53K
- Open
- 1.37
- Previous close
- 1.37
- Day's range
- 1.33 – 1.42
- 52-week range
- 1.02 – 1.91
- Beta
- 1.48
- Price target
- 5.80 (+320.3%)
- Earnings date
- Aug 8, 2024
1m +0.03 (+2.26%)
Key statistics
- Enterprise value
- -91.95M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -39.68M
- Total cash
- 182.84M
- Total debt
- 13.27M
- Return on equity
- -23.63%
- Short % of float
- 2.01%
- 50-day average
- 1.61
- 200-day average
- 1.65
Analyst view
Price target (mean) 5.80 +320.3% upside
Now 1.38
- Target (low)
- 5.00
- Target (mean)
- 5.80
- Target (high)
- 7.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.3825.
Financials — quick view
PMVP Revenue — quarterly 0
PMVP Net income — quarterly -18.09M
PMVP EPS — quarterly -0.34
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.35 | -0.37 | -0.02 | -5.71% |
| Aug 8, 2024 | Jun 1, 2024 | -0.34 | -0.02 | +0.32 | +94.12% |
| Aug 8, 2024 | Jun 1, 2024 | -0.34 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.35 | -0.30 | +0.05 | +14.29% |
| May 9, 2024 | Mar 1, 2024 | -0.35 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.39 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 13, 2024 | Craig-Hallum | init | — | Buy |
| Apr 12, 2024 | Jefferies | init | — | Buy |
| Mar 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pmvpharma.com
News
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know 
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity 
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Has Consensus Target Price of $4.33 According to Analysts 
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? 
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push 
Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket 
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities 
PMV Pharma Announces Proposed Public Offering of Securities 
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial 
PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?
Your note
Sign in to keep a note on PMVP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLAND LEILA | Officer | Sale | Sep 14, 2023 | 45,909 |
| CARULLI MICHAEL | Chief Financial Officer | Sale | Sep 10, 2024 | 88,395 |
| JALOTA DEEPIKA | Officer | Sale | Sep 10, 2024 | 118,283 |
| MACK DAVID HENRY | Chief Executive Officer | Stock Award(Grant) | Jan 17, 2024 | 812,660 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 21, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 12.51% | 6,475,291 | 9.78M | Sep 29, 2024 |
| ArrowMark Colorado Holdings LLC | 7.05% | 3,647,291 | 5.51M | Sep 29, 2024 |
| Sio Capital Management, LLC | 6.21% | 3,214,239 | 4.85M | Sep 29, 2024 |
| Euclidean Capital Llc | 5.08% | 2,627,643 | 3.97M | Sep 29, 2024 |
| Alkeon Capital Management LLC | 4.53% | 2,343,731 | 3.54M | Sep 29, 2024 |
| Vanguard Group Inc | 4.41% | 2,280,803 | 3.44M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.95% | 1,524,487 | 2.30M | Sep 29, 2024 |
| Meridian Small Cap Growth Fund | 2.43% | 1,255,473 | 1.90M | Sep 29, 2024 |
| ACAP Strategic Fund | 2.22% | 1,147,095 | 1.73M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.04% | 540,351 | 815.93K | Sep 29, 2024 |
| Advantage Advisers Xanthus Fund, LLC | 0.64% | 329,949 | 498.22K | Sep 29, 2024 |
| BlackRock Advantage Small Cap Core Fund | 0.54% | 280,445 | 423.47K | Aug 30, 2024 |